triazoles has been researched along with Age-Related Osteoporosis in 33 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.03) | 18.2507 |
| 2000's | 9 (27.27) | 29.6817 |
| 2010's | 23 (69.70) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kaur, J; Tikoo, K; Vekariya, KK | 1 |
| Balaez, A; Beck, DT; Beggs, LA; Borst, SE; Combs, SM; Conover, CF; Lachacz, SA; Leeper, AM; Miller, JR; Otzel, DM; Williams, AA; Wronski, TJ; Yarrow, JF; Ye, F; Zheng, N | 1 |
| Liu, M; Liu, P; Xie, F; Yang, DQ; Zhou, B | 1 |
| Batzler, A; Carlson, EE; Chapman, JA; Ellis, MJ; Furukawa, Y; Goss, PE; Ingle, JN; Jenkins, GD; Khosla, S; Kubo, M; Liu, M; Nakamura, Y; Schaid, DJ; Shepherd, LE; Wang, L; Weinshilboum, RM | 1 |
| Amendola, G; Casale, M; Cinque, P; Citarella, S; De Michele, E; Della Rocca, F; Filosa, A; Nobili, B; Palmieri, F; Perrotta, S; Pugliese, U; Ragozzino, A; Tartaglione, I | 1 |
| Phillips, R | 1 |
| Blake, GM; Coleman, R; Cuzick, J; Dowsett, M; Eastell, R; Forbes, JF; Gossiel, F; Howell, A; Patel, R; Sestak, I; Singh, S | 1 |
| Makhoul, I; Suva, LJ | 1 |
| Ayşe Demirel, M; İlhan, M; Keleş, H; Küpeli Akkol, E; Süntar, İ; Tümen, I | 1 |
| Atherton, PJ; Dakhil, SR; Hines, SL; Lafky, JM; Loprinzi, CL; Majithia, N; Olson, J; Perez, EA; Wagner-Johnston, N | 1 |
| Daniele, C; Equitani, F; Guitarrini, MR; Losardo, A; Maffei, L; Monti, S; Pasin, M; Poggi, M; Pugliese, P; Smacchia, MP; Sorrentino, F; Terlizzi, F; Toscano, V | 1 |
| Amiaud, J; Baud'huin, M; Berreur, M; Bradner, JE; Brounais-LeRoyer, B; Charrier, C; Heymann, D; Jacques, C; Lamoureux, F; Ory, B; Owen, R; Quillard, T; Reilly, GC; Rodriguez Calleja, L | 1 |
| Guo, W; Huang, XH; Liang, RH; Su, L; Wang, CJ | 1 |
| Giorgadze, E; Khachidze, N; Tsagareli, M | 1 |
| Bjelic-Radisic, V; Dubsky, P; Fitzal, F; Gnant, M; Greil, R; Jakesz, R; Kainberger, F; Kässmann, H; Kubista, E; Luschin-Ebengreuth, G; Marth, C; Menzel, C; Mittlböck, M; Mlineritsch, B; Piswanger-Sölkner, JC; Ploner, F; Samonigg, H; Seifert, M; Steger, G; Wohlmuth, P | 1 |
| Gibson, K; O'Bryant, CL | 1 |
| El-Mardenly, G; Ezzat, Y; Gheita, TA; Hammam, W; Sayed, S | 1 |
| Atherton, PJ; Dakhil, SR; Dalton, RJ; Hines, SL; Johnson, DB; Loprinzi, CL; Mattar, BI; Perez, EA; Reddy, PS; Sloan, JA | 1 |
| Markopoulos, C | 1 |
| Tang, SC | 1 |
| Aebi, S; Berthod, G; Brauchli, P; Genton, C; Giobbie-Hurder, A; Huober, J; Lüthi, J; Pagani, O; Schönenberger, A; Simcock, M; Thürlimann, B; Zaman, K | 1 |
| Al-Soud, YA; Hartmann, RW; Marchais-Oberwinkler, S; Wetzel, M; Xu, K | 1 |
| Gogas, H; Koukouras, D; Markopoulos, C; Misitzis, J; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V | 1 |
| Chan, FL; Chen, S; Cheung, WH; Chow, S; Leung, LK; Li, F | 1 |
| Ansari, RH; Budd, GT; Chalchal, H; Chapman, JA; D'Souza, DP; Elliott, C; Ellis, MJ; Gelmon, KA; Goss, PE; Ingle, JN; Johnson, DB; Lang, I; Liedke, PE; Perez, EA; Pritchard, KI; Rabaglio, M; Shepherd, LE; Sledge, GW; Spadafora, S; Stearns, V; Tozer, R | 1 |
| Coleman, RE | 1 |
| Aumiller, J | 1 |
| Bhatnagar, AS; Evans, DB; Gasser, JA; Green, JR; Ingold, P; Rebmann, A; Shen, V | 1 |
| Gralow, JR | 1 |
| Douchi, T; Iwamoto, I; Kosha, S; Rai, Y; Sagara, Y; Yonehara, Y | 1 |
| Perez, EA | 1 |
| Bouillon, R; De Coster, R; Van Herck, E; Vanderschueren, D | 1 |
| Alba, E; Colla, F; Farina, C; Mazzoleni, A; Ragonesi, G | 1 |
5 review(s) available for triazoles and Age-Related Osteoporosis
| Article | Year |
|---|---|
ADJUVANT (HORMONAL) THERAPY AS A CAUSE OF BONE LOSS IN PATIENTS WITH BREAST CANCER (REVIEW OF LITERATURE).
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Letrozole; Nitriles; Osteoporosis; Postmenopause; Premenopause; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2017 |
Women and bone health: maximizing the benefits of aromatase inhibitor therapy.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Breast Neoplasms; Colorectal Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Letrozole; Nitriles; Osteoporosis; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; RANK Ligand; Secondary Prevention; Tamoxifen; Triazoles; Zoledronic Acid | 2010 |
Current and future status of adjuvant therapy for breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Female; Forecasting; Humans; Nitriles; Osteoporosis; Receptors, Estrogen; Tamoxifen; Triazoles | 2003 |
Safety of aromatase inhibitors in the adjuvant setting.
Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Causality; Chemotherapy, Adjuvant; Comorbidity; Estrogen Receptor Modulators; Female; Hot Flashes; Humans; Incidence; Letrozole; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Nitriles; Osteoporosis; Rats; Survival Analysis; Tamoxifen; Triazoles | 2007 |
[Antiestrogen therapy in the treatment of breast neoplasms].
Topics: Adult; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; Estrogen Antagonists; Female; Forecasting; Humans; Indoles; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Toremifene; Triazoles | 2002 |
7 trial(s) available for triazoles and Age-Related Osteoporosis
| Article | Year |
|---|---|
Effect of calcitonin on anastrozole-induced bone pain during aromatase inhibitor therapy for breast cancer.
Topics: Absorptiometry, Photon; Aged; Alkaline Phosphatase; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Calcitonin; Calcium; Female; Femur; Humans; Middle Aged; Nitriles; Osteocalcin; Osteoporosis; Pain; Phosphorus; Spine; Triazoles | 2014 |
Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomics.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density; Female; Gene-Environment Interaction; Genome-Wide Association Study; Genotype; Humans; Middle Aged; Nitriles; Osteoporosis; Osteoporotic Fractures; Polymorphism, Single Nucleotide; Triazoles | 2014 |
Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with β-thalassemia major.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Bone and Bones; Bone Density; Calcium; Chelation Therapy; Child; Child, Preschool; Deferasirox; Diabetes Mellitus; Diphosphonates; Female; Humans; Hypogonadism; Hypoparathyroidism; Hypothyroidism; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Osteoporosis; Puberty, Delayed; Retrospective Studies; Triazoles; Vitamin D | 2014 |
Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial.
Topics: Adult; Aged; Anastrozole; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Etidronic Acid; Female; Follow-Up Studies; Humans; International Agencies; Middle Aged; Nitriles; Osteoporosis; Postmenopause; Prognosis; Risedronic Acid; Triazoles | 2014 |
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Goserelin; Humans; Imidazoles; Linear Models; Nitriles; Osteoporosis; Premenopause; Prospective Studies; Tamoxifen; Triazoles; Zoledronic Acid | 2008 |
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy.
Topics: Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Humans; Imidazoles; Letrozole; Nitriles; Osteoporosis; Risk Factors; Treatment Outcome; Triazoles; Zoledronic Acid | 2010 |
Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Female; Follow-Up Studies; History, 18th Century; Hot Flashes; Humans; Hypercholesterolemia; Kaplan-Meier Estimate; Middle Aged; Nitriles; Osteoporosis; Postmenopause; Time Factors; Treatment Outcome; Triazoles | 2013 |
21 other study(ies) available for triazoles and Age-Related Osteoporosis
| Article | Year |
|---|---|
Alleviating anastrozole induced bone toxicity by selenium nanoparticles in SD rats.
Topics: Alkaline Phosphatase; Anastrozole; Animals; Aromatase Inhibitors; Bone and Bones; Cells, Cultured; Female; Humans; Nanoparticles; Nitriles; Osteoblasts; Osteoporosis; Rats; Rats, Sprague-Dawley; Selenium; Triazoles | 2013 |
Influence of aromatase inhibition on the bone-protective effects of testosterone.
Topics: Anabolic Agents; Anastrozole; Androgens; Animals; Aromatase; Aromatase Inhibitors; Heptanoates; Male; Muscle, Skeletal; Nitriles; Orchiectomy; Osteoporosis; Rats; Rats, Inbred F344; Testosterone; Trenbolone Acetate; Triazoles | 2014 |
Breast cancer. Risedronate reduces bone loss.
Topics: Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Nitriles; Osteoporosis; Postmenopause; Triazoles | 2015 |
Bone: Will breast cancer chemoprevention stand on 'solid bone'?
Topics: Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Nitriles; Osteoporosis; Postmenopause; Triazoles | 2015 |
Thuja occidentalis L. and its active compound, α-thujone: Promising effects in the treatment of polycystic ovary syndrome without inducing osteoporosis.
Topics: Animals; Bicyclic Monoterpenes; Blood Glucose; Catalase; Estradiol; Female; Glutathione Peroxidase; Leptin; Letrozole; Lipids; Luteinizing Hormone; Malondialdehyde; Monoterpenes; Nitriles; Oils, Volatile; Osteoporosis; Phytotherapy; Polycystic Ovary Syndrome; Progesterone; Rats, Sprague-Dawley; Superoxide Dismutase; Testosterone; Thuja; Triazoles | 2015 |
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up.
Topics: Adjuvants, Pharmaceutic; Aged; Aged, 80 and over; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Imidazoles; Letrozole; Lumbar Vertebrae; Middle Aged; Nitriles; Osteoporosis; Triazoles; Zoledronic Acid | 2016 |
Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years.
Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Diabetes Mellitus; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypogonadism; Hypothyroidism; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Osteoporosis; Prevalence; Pyridones; Retrospective Studies; Transfusion Reaction; Triazoles | 2016 |
Inhibition of BET proteins and epigenetic signaling as a potential treatment for osteoporosis.
Topics: Animals; Azepines; Biomechanical Phenomena; Cell Count; Cell Differentiation; Epigenesis, Genetic; Female; Humans; Mice, Inbred C57BL; Nuclear Proteins; Organ Size; Osteoblasts; Osteoclasts; Osteoporosis; Ovariectomy; Signal Transduction; Triazoles | 2017 |
Mechanism of Bushen Jianpi decoction in preventing and treating osteoporosis caused by aromatase inhibitors in breast cancer treatment.
Topics: Alendronate; Alkaline Phosphatase; Anastrozole; Animals; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Disease Models, Animal; Drugs, Chinese Herbal; Female; Mice, Inbred BALB C; Nitriles; Osteoporosis; Ovariectomy; Triazoles | 2017 |
Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitriles; Osteoporosis; Retrospective Studies; Triazoles | 2008 |
Musculoskeletal manifestations in patients with malignant disease.
Topics: Adult; Aged; Analysis of Variance; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Humans; Joint Diseases; Letrozole; Male; Middle Aged; Muscular Diseases; Neoplasms; Nitriles; Osteoporosis; Statistics, Nonparametric; Triazoles | 2010 |
Managing bone health in women with breast cancer under adjuvant treatment with aromatase inhibitors: pretreatment bone mineral density is important.
Topics: Anastrozole; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Drug Therapy, Combination; Female; Humans; Nitriles; Osteoporosis; Triazoles | 2010 |
Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Breast Neoplasms; Female; Hip; Humans; Letrozole; Lumbar Vertebrae; Middle Aged; Multivariate Analysis; Nitriles; Osteoporosis; Postmenopause; Radiography; Randomized Controlled Trials as Topic; Retrospective Studies; Tamoxifen; Triazoles | 2012 |
Triazole ring-opening leads to the discovery of potent nonsteroidal 17β-hydroxysteroid dehydrogenase type 2 inhibitors.
Topics: Drug Discovery; Enzyme Inhibitors; Estradiol Dehydrogenases; Estrogen Receptor alpha; Estrogen Receptor beta; Humans; Osteoporosis; Structure-Activity Relationship; Triazoles | 2011 |
Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial.
Topics: Absorptiometry, Photon; Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Drug Therapy, Combination; Etidronic Acid; Female; Humans; Middle Aged; Nitriles; Osteoporosis; Osteoporosis, Postmenopausal; Outcome and Process Assessment, Health Care; Prospective Studies; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Assessment; Risk Factors; Time Factors; Triazoles | 2012 |
The citrus flavonone hesperetin prevents letrozole-induced bone loss in a mouse model of breast cancer.
Topics: Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Citrus; Estradiol; Female; Hesperidin; Humans; Letrozole; MCF-7 Cells; Mice; Mice, Nude; Nitriles; Osteoporosis; Selective Estrogen Receptor Modulators; Triazoles; Xenograft Model Antitumor Assays | 2013 |
[Breast carcinoma: new, much promising trends. The cancer anxiety of women -- will be taken better care soon?].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Austria; Breast Neoplasms; Clinical Trials as Topic; Female; Fractures, Bone; Germany; Humans; Mammography; Middle Aged; Multicenter Studies as Topic; Nitriles; Osteoporosis; Randomized Controlled Trials as Topic; Risk; Risk Factors; Tamoxifen; Time Factors; Triazoles | 2005 |
A single intravenous administration of zoledronic acid prevents the bone loss and mechanical compromise induced by aromatase inhibition in rats.
Topics: Animals; Aromatase Inhibitors; Biomechanical Phenomena; Body Weight; Bone and Bones; Bone Density; Bone Density Conservation Agents; Diphosphonates; Estrogens; Female; Imidazoles; Injections, Intravenous; Letrozole; Nitriles; Organ Size; Osteocalcin; Osteoporosis; Ovariectomy; RANK Ligand; Rats; Rats, Wistar; Triazoles; Uterus; Zoledronic Acid | 2006 |
Bone density in breast cancer: when to intervene?
Topics: Absorptiometry, Photon; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Goserelin; Humans; Imidazoles; Nitriles; Osteoporosis; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles; Zoledronic Acid | 2007 |
Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Drug Interactions; Etidronic Acid; Female; Humans; Middle Aged; Nitriles; Osteoporosis; Postmenopause; Risedronic Acid; Triazoles | 2007 |
Aromatization of androgens is important for skeletal maintenance of aged male rats.
Topics: Absorptiometry, Photon; Aging; Amino Acids; Analysis of Variance; Androgens; Animals; Aromatase Inhibitors; Bone Density; Bone Development; Bone Resorption; Calcium; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Estrogens; Femur; Lumbar Vertebrae; Male; Orchiectomy; Osteocalcin; Osteoporosis; Rats; Rats, Wistar; Triazoles | 1996 |